Progyny Expands Global Benefits to Include Pregnancy, Postpartum, and Menopause

Rhea-AI Summary

Progyny (Nasdaq: PGNY) announced a global expansion of benefits to include pregnancy, postpartum, and menopause programs, available to employers starting January 1, 2026. The offerings complement Progyny’s existing global fertility and family building services to provide an integrated continuum across life stages.

Key features include personalized Global Care Advocates, a curated evidence-based knowledge center, country-specific navigator support, and a GDPR-compliant benefits platform. The program supports employees in more than 127 countries with multilingual capabilities.

Positive

• Launch date set for January 1, 2026
• Multilingual support covering employees in 127 countries
• GDPR-compliant platform for regional privacy requirements
• Integrates with existing global fertility and family building offering

Negative

• None.

Insights

Global Benefits Strategist

Progyny's launch of pregnancy, postpartum, and menopause programs for global employers broadens its benefits suite and should strengthen employer value proposition.

Progyny expands its existing global fertility and family building offering with integrated pregnancy, postpartum, and menopause programs available January 1, 2026. The package bundles personalized consultations, a curated knowledge center, country-specific navigator support, and a GDPR-compliant platform, all framed as multilingual coverage across more than 127 countries. This creates a unified, administrable benefit that employers can offer across multiple jurisdictions without stitching disparate vendors together.

Key dependencies and risks include employer uptake, regional regulatory differences, and operational execution of local navigation at scale. The release cites a UK finding that 10% of working women left a job due to menopause symptoms and references a McKinsey estimate that closing women's health gaps could add $1 trillion to the global economy by 2040, but no client commitments, pricing, or measurable pilot outcomes are disclosed. Success will hinge on sales adoption, measurable utilization, and local provider network depth.

Watch for early adoption signals and concrete metrics within the next 6–12 months: employer contract announcements, utilization rates for the new programs, case studies on cross-border administration, and any disclosed client savings or retention data. Those items will materially clarify whether this expands market share or remains a product extension with limited traction.

Global employers can now empower their workforces with comprehensive women’s health benefits, supported by localized expertise

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced the launch of its pregnancy, postpartum, and menopause programs for global employers, available starting January 1, 2026. These offerings complement the availability of the company’s existing and marketing-leading global fertility and family building offering, providing multi-national employers with a continuum of integrated services. Progyny’s localized global expertise and member-first experience are supporting unmet needs across pivotal women’s and family life stages.

Global employers are recognizing the need to offer specialized care for women in the workforce, as supported by a UK study that showed 1 in 10 working women left a job due to menopause symptoms. Progyny's platform was purpose-built for global markets, supporting members in their country-specific environment, helping them with expert support through stages of pregnancy, postpartum, menopause, and midlife to optimize health, productivity, and retention. Employees uniquely have access to:

• Personalized consultations and guided programs with Global Care Advocates, with maternal health, menopause, and mental health expertise.
• A curated knowledge center for evidence-based education on symptoms, work-life balance, relationships, emotional well-being, and mental health.
• Country-specific navigator support for local care, regulations, policies, and protections.
• A GDPR-compliant platform and benefit administration tailored to meet the unique needs of different regions.

“We’ve done extensive research and heard from employers that a clear gap exists – they need local market expertise and real partnership for their employees. Progyny’s global offerings combine our recognized focus on clinical expertise with localized guidance, helping members find and connect to the right care at the right time, wherever our members live,” says Jenny Saft, General Manager of Global Markets, Progyny. “For global employers, this means a unified women’s health solution that provides expert-led human support while simplifying benefit administration across regions.”

According to a McKinsey study, closing gaps in women’s health globally could add $1 trillion to the global economy by 2040. By combining country-specific expertise with global scale, Progyny is uniquely meeting employer needs with highly sought, specialized knowledge to support employees’ needs including assistance comprehending public coverage, understanding referral requirements, and navigating leave rules. This unique approach delivers meaningful, cohesive guidance designed to support language and cultural needs.

The Progyny Global experience is multilingual, covering the most common languages spoken in more than 127 countries with the capabilities to support employees in every country around the world.

For more information on Progyny Global, visit https://progynyglobal.com/

About Progyny

Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians.

Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.

Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

For Further Information, Please Contact:
Media:
Alexis Ford
media@progyny.com

Investors:
James Hart
investors@progyny.com

FAQ

When will Progyny (PGNY) make its pregnancy, postpartum, and menopause programs available to employers?

Progyny will make the global programs available starting January 1, 2026.

Which countries and languages does Progyny Global (PGNY) support for pregnancy and menopause benefits?

Progyny Global provides multilingual support covering employees in more than 127 countries.

How does Progyny (PGNY) handle data privacy for its global benefits platform?

The company operates a GDPR-compliant platform and benefit administration tailored to regional needs.

What types of support are included in Progyny's (PGNY) new women’s health programs?

Programs include personalized consultations with Global Care Advocates, a curated knowledge center, and country-specific navigator support.

Will Progyny's (PGNY) pregnancy and menopause offerings integrate with existing fertility benefits?

Yes; the new programs are designed to complement and integrate with Progyny’s existing global fertility and family building offering.

What employer outcomes does Progyny (PGNY) highlight for offering these global women’s health benefits?

Progyny emphasizes improved employee health, productivity, and retention through localized clinical support and simplified benefit administration.